Menu
GeneBe

PIK3C2A

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha, the group of Phosphatidylinositol 3-kinase subunits

Basic information

Region (hg38): 11:17077729-17207986

Links

ENSG00000011405NCBI:5286OMIM:603601HGNC:8971Uniprot:O00443AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • oculocerebrodental syndrome (Supportive), mode of inheritance: AR
  • oculocerebrodental syndrome (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Oculoskeletodental syndromeARAudiologic/Otolaryngologic; OphthalmologicEarly recognition and treatment of hearing impairment may improve outcomes, including speech and language development; The condition can include secondary glaucoma, and awareness may allow prompt diagnosis and managementAudiologic/Otolaryngologic; Craniofacial; Endocrine; Musculoskeletal; Neurologic; Ophthalmologic31034465

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PIK3C2A gene.

  • not provided (270 variants)
  • Inborn genetic diseases (55 variants)
  • Oculocerebrodental syndrome (7 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PIK3C2A gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
63
clinvar
13
clinvar
78
missense
145
clinvar
12
clinvar
9
clinvar
166
nonsense
4
clinvar
1
clinvar
5
start loss
0
frameshift
3
clinvar
3
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
0
splice region
6
13
2
21
non coding
2
clinvar
32
clinvar
8
clinvar
42
Total 7 1 151 107 30

Highest pathogenic variant AF is 0.0000131

Variants in PIK3C2A

This is a list of pathogenic ClinVar variants found in the PIK3C2A region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-17089725-A-G Oculocerebrodental syndrome Benign (Sep 05, 2021)1327026
11-17089741-C-T Likely benign (Jan 20, 2024)1623310
11-17089753-C-T Likely benign (May 03, 2022)2164260
11-17089754-G-A not specified Uncertain significance (Aug 17, 2022)2081517
11-17089766-T-C Uncertain significance (Apr 19, 2022)1911263
11-17089777-C-T Likely benign (Dec 09, 2023)2192392
11-17089778-G-A not specified Uncertain significance (Jan 16, 2024)1930264
11-17089793-T-C Likely benign (Sep 03, 2022)2200468
11-17089802-T-C Uncertain significance (Mar 04, 2022)1906752
11-17089825-C-T Likely benign (May 27, 2022)1928798
11-17089842-G-A Uncertain significance (Oct 13, 2023)1937047
11-17089857-T-C Uncertain significance (May 12, 2022)1931706
11-17089924-C-T Likely benign (Apr 28, 2023)2169043
11-17091315-A-T Benign (Nov 03, 2023)1987017
11-17091349-C-T Likely benign (May 03, 2023)2991337
11-17091350-G-A Uncertain significance (May 18, 2022)1934274
11-17091358-C-T Likely benign (Sep 27, 2022)2073552
11-17091383-C-G Uncertain significance (Jul 05, 2022)2064381
11-17091395-T-C not specified Uncertain significance (Sep 01, 2021)2405466
11-17091408-G-C not specified Uncertain significance (Aug 02, 2021)2364815
11-17091426-C-G not specified Uncertain significance (May 09, 2023)2545723
11-17091430-T-C PIK3C2A-related disorder Benign/Likely benign (Jan 29, 2024)1665149
11-17091441-C-A Uncertain significance (Jul 20, 2022)1720994
11-17091531-C-A Likely benign (Jun 29, 2023)2719956
11-17091552-C-A Uncertain significance (Jul 14, 2022)1946850

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PIK3C2Aprotein_codingprotein_codingENST00000265970 32130254
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.01010.9901256960501257460.000199
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.307498560.8750.000042211066
Missense in Polyphen233351.060.663714629
Synonymous1.312672960.9030.00001453174
Loss of Function6.592390.70.2540.000005121094

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0002120.000212
Ashkenazi Jewish0.00009920.0000992
East Asian0.00005440.0000544
Finnish0.00009270.0000924
European (Non-Finnish)0.0003270.000325
Middle Eastern0.00005440.0000544
South Asian0.0001330.000131
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. Has a role in several intracellular trafficking events. Functions in insulin signaling and secretion. Required for translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane and glucose uptake in response to insulin- mediated RHOQ activation. Regulates insulin secretion through two different mechanisms: involved in glucose-induced insulin secretion downstream of insulin receptor in a pathway that involves AKT1 activation and TBC1D4/AS160 phosphorylation, and participates in the late step of insulin granule exocytosis probably in insulin granule fusion. Synthesizes PtdIns3P in response to insulin signaling. Functions in clathrin-coated endocytic vesicle formation and distribution. Regulates dynamin- independent endocytosis, probably by recruiting EEA1 to internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on large dense core vesicles. Participates in calcium induced contraction of vascular smooth muscle by regulating myosin light chain (MLC) phosphorylation through a mechanism involving Rho kinase-dependent phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role in the EGF signaling cascade. May be involved in mitosis and UV-induced damage response. Required for maintenance of normal renal structure and function by supporting normal podocyte function. {ECO:0000269|PubMed:10766823, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:12719431, ECO:0000269|PubMed:16215232, ECO:0000269|PubMed:21081650, ECO:0000269|PubMed:9337861}.;
Pathway
Inositol phosphate metabolism - Homo sapiens (human);Phosphatidylinositol signaling system - Homo sapiens (human);Proton Pump Inhibitor Pathway, Pharmacodynamics;Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics;Sorafenib Pharmacodynamics;VEGF Signaling Pathway;Phosphatidylinositol Phosphate Metabolism;Joubert syndrome;Signaling Pathways in Glioblastoma;Integrated Lung Cancer Pathway;Angiopoietin Like Protein 8 Regulatory Pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Microglia Pathogen Phagocytosis Pathway;Insulin Signaling;Regulation of Actin Cytoskeleton;DNA Damage Response (only ATM dependent);Golgi Associated Vesicle Biogenesis;Clathrin derived vesicle budding;trans-Golgi Network Vesicle Budding;Vesicle-mediated transport;Membrane Trafficking;Metabolism of lipids;Inositol phosphate metabolism;Metabolism;3-phosphoinositide biosynthesis;superpathway of inositol phosphate compounds;Phosphatidylinositol phosphate metabolism;Clathrin-mediated endocytosis;Synthesis of PIPs at the Golgi membrane;Synthesis of PIPs at the early endosome membrane;Synthesis of PIPs at the plasma membrane;Synthesis of PIPs at the late endosome membrane;PI Metabolism;Phospholipid metabolism;Integrins in angiogenesis (Consensus)

Recessive Scores

pRec
0.636

Intolerance Scores

loftool
0.657
rvis_EVS
-1.48
rvis_percentile_EVS
3.72

Haploinsufficiency Scores

pHI
0.606
hipred
Y
hipred_score
0.706
ghis
0.649

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.988

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Pik3c2a
Phenotype
growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; renal/urinary system phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype;

Zebrafish Information Network

Gene name
pik3c2a
Affected structure
intersegmental vessel
Phenotype tag
abnormal
Phenotype quality
process quality

Gene ontology

Biological process
phosphatidylinositol biosynthetic process;exocytosis;endocytosis;epidermal growth factor receptor signaling pathway;insulin receptor signaling pathway;phosphatidylinositol 3-kinase signaling;vascular smooth muscle contraction;cell migration;phosphatidylinositol-3-phosphate biosynthetic process;phosphatidylinositol phosphorylation;platelet-derived growth factor receptor signaling pathway;phosphatidylinositol-mediated signaling;clathrin coat assembly;membrane organization;positive regulation of cell migration involved in sprouting angiogenesis
Cellular component
nucleus;cytoplasm;Golgi apparatus;cytosol;plasma membrane;phosphatidylinositol 3-kinase complex;membrane;clathrin-coated vesicle;vesicle;extracellular exosome
Molecular function
ATP binding;1-phosphatidylinositol-3-kinase activity;phosphatidylinositol 3-kinase activity;1-phosphatidylinositol-4-phosphate 3-kinase activity;phosphatidylinositol binding